New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and […]
FREISING, GERMANY, February 12, 2015 – XL-protein GmbH, Germany, a privately owned biopharmaceutical company, announced today that they have entered into a license agreement with MSD Animal Health (known as Merck Animal Health in the USA and Canada) to develop PASylated biopharmaceuticals for use in animal health. This license agreement follows a research collaboration between […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00XL-proteinhttps://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngXL-protein2015-02-12 12:52:392016-09-26 16:29:04XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals using its PASylation® Technology
FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014 – Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist – PAS-YNSα8 – which has been jointly developed […]
https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png00XL-proteinhttps://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.pngXL-protein2014-10-21 12:55:572016-09-26 16:32:01XL-protein and YEDA sign business collaboration agreement to commercialize PASylated interferon superagonist
DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharmaceutical Products
New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and […]
XL-protein Signs Licensing Agreement with MSD Animal Health to Develop Biopharmaceuticals using its PASylation® Technology
FREISING, GERMANY, February 12, 2015 – XL-protein GmbH, Germany, a privately owned biopharmaceutical company, announced today that they have entered into a license agreement with MSD Animal Health (known as Merck Animal Health in the USA and Canada) to develop PASylated biopharmaceuticals for use in animal health. This license agreement follows a research collaboration between […]
XL-protein and YEDA sign business collaboration agreement to commercialize PASylated interferon superagonist
FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014 – Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist – PAS-YNSα8 – which has been jointly developed […]